Reuters HealthJun 20, 2026
First CRISPR Treatment for Sickle Cell Disease Approved in Europe
European regulators have approved the first gene-editing therapy using CRISPR technology to treat sickle cell disease, offering a potential one-time cure.

The therapy works by editing a patient’s own stem cells to produce fetal hemoglobin, compensating for the defective adult hemoglobin that causes the disease. Clinical trials showed 94% of treated patients remained free of severe pain crises.
Continue Reading
This is a syndicated excerpt. To read the full story and view all associated media, please visit the original publisher.
Read Full Article at Reuters Health